Circulating microRNAs (miRNAs), especially transported by extracellular vesicles (EVs), have recently emerged as major new participants in interorgan communication, playing an important role in the metabolic coordination of our tissues. Among these, adipose tissue displays an extraordinary ability to secrete a vast list of EV-carried miRNAs into the circulation, representing new hormone-like factors. Despite the limitations of current methodologies for the unequivocal identification of the origin and destination of EV-carried miRNAs in vivo, recent investigations clearly support the important regulatory role of adipose-derived circulating miRNAs in shaping the metabolism and function of other tissues including the liver, muscle, endocrine pancreas, cardiovascular system, gastrointestinal tract, and brain. Here, we review the most recent findings regarding miRNAs transported by adipose-derived EVs (AdEVs) targeting other major metabolic organs and the implications of this dialog for physiology and pathology. We also review here the current and potential future diagnostic and therapeutic applications of AdEV-carried miRNAs.
Oxidative stress-induced myocardial apoptosis and necrosis are critically involved in ischemic infarction, and several sources of extracellular vesicles appear to be enriched in therapeutic activities. The central objective was to identify and validate the differential exosome miRNA repertoire in human cardiac progenitor cells (CPC). CPC exosomes were first analyzed by LC-MS/MS and compared by RNAseq with exomes of human mesenchymal stromal cells and human fibroblasts to define their differential exosome miRNA repertoire (exo-miRSEL). Proteomics demonstrated a highly significant representation of cardiovascular development functions and angiogenesis in CPC exosomes, and RNAseq analysis yielded about 350 different miRNAs; among the exo-miRSEL population, miR-935 was confirmed as the miRNA most significantly up-regulated; interestingly, miR-935 was also found to be preferentially expressed in mouse primary cardiac Bmi1+high CPC, a population highly enriched in progenitors. Furthermore, it was found that transfection of an miR-935 antagomiR combined with oxidative stress treatment provoked a significant increment both in apoptotic and necrotic populations, whereas transfection of a miR-935 mimic did not modify the response. Conclusion. miR-935 is a highly differentially expressed miRNA in exo-miRSEL, and its expression reduction promotes oxidative stress-associated apoptosis. MiR-935, together with other exosomal miRNA members, could counteract oxidative stress-related apoptosis, at least in CPC surroundings.
Enhancing thermogenic brown adipose tissue (BAT) function is a promising therapeutic strategy for metabolic disease. However, predominantly thermoneutral modern human living conditions deactivate BAT. We demonstrate that selective adipocyte deficiency of the oxygen-sensor HIF-prolyl hydroxylase (PHD2) gene overcomes BAT dormancy at thermoneutrality. Adipocyte-PHD2-deficient mice maintain higher energy expenditure having greater BAT thermogenic capacity. In human and murine adipocytes, a PHD inhibitor increases Ucp1 levels. In murine brown adipocytes, antagonising the major PHD2 target, hypoxia-inducible factor-(HIF)−2a abolishes Ucp1 that cannot be rescued by PHD inhibition. Mechanistically, PHD2 deficiency leads to HIF2 stabilisation and binding of HIF2 to the Ucp1 promoter, thus enhancing its expression in brown adipocytes. Serum proteomics analysis of 5457 participants in the deeply phenotyped Age, Gene and Environment Study reveal that serum PHD2 associates with increased risk of metabolic disease. Here we show that adipose-PHD2-inhibition is a therapeutic strategy for metabolic disease and identify serum PHD2 as a disease biomarker.
5 March 2014 in Experimental and Clinical Endocrinology & Diabetes
The inflammatory state present in obesity contributes to obesity-related metabolic dysregulation, including non-alcoholic steatohepatitis (NASH) and insulin resistance. Intercellular interactions between immune cells or between immune cells and hepatic parenchymal cells contribute to the exacerbation of liver inflammation and steatosis in obesity. The co-stimulatory molecules B7.1 and B7.2 are important regulators of cell-cell interactions in several immune processes; however, the role of B7 co-stimulation in obesity-related liver inflammation is still unknown. Here, diet-induced obesity (DIO) studies in mice with genetic inactivation of both B7.1 and B7.2 (Dko) revealed aggravated obesity-related metabolic dysregulation, glucose intolerance and enhanced progression to steatohepatitis due to B7.1/B7.2-double deficiency. The metabolic phenotype of B7.1/B7.2-double deficiency upon DIO was accompanied by increased hepatic and adipose tissue inflammation, associated with largely reduced numbers of regulatory T cells (Tregs) in these organs. In order to assess the role of B7co-stimulation in DIO in a non-Treg lacking environment, we performed antibody-mediated inhibition of B7 molecules in wild-type mice in DIO. Antibody-blockade of both B7.1 and B7.2, but not of either one alone, improved the metabolic phenotype of DIO-mice, which was linked to amelioration of hepatic steatosis and reduced inflammation in liver and adipose tissue. Our study demonstrates a dual role of B7 co-stimulation in the course of obesity-related sequelae, particularly NASH. The genetic inactivation of B7.1/B7.2 deteriorates obesity-related liver steatosis and metabolic dysregulation likely due to the intrinsic absence of Tregs in these mice rendering Dko mice a novel murine model of NASH in future studies. In contrast, inhibition of B7 co-stimulation under conditions, where Tregs are present, may provide a novel therapeutic approach for obesity-related metabolic dysregulation and especially NASH.
Many genes share promoters with another gene on the opposite DNA strand, forming bidirectional pairs. During metabolic transitions, most pairs are coordinately regulated in the liver, in part through chromatin topology. In pairs composed of a long noncoding RNA (lncRNA) and a protein-coding gene (PCG), lncRNA transcription cis-activates PCG transcription by establishing an active chromatin environment at the promoter-proximal enhancer of PCG. Reciprocally, PCG transcription cis-inhibits lncRNA transcription, forming internal cis-autoregulatory circuits. Both directions of regulation are independent of the RNA products but dependent on the transcription process itself. Similar promoter-proximal enhancer signatures and cis-autoregulatory circuits are present in many lncRNA/PCG and PCG/PCG pairs, underscoring the generalizability of these circuits. Using the conserved lncRNA/PCG pair Gm15663 / Tmtc2 as a model, we show that blocking lncRNA transcription in the liver in vivo disrupts this coordinated regulation, decreasing Tmtc2 expression and inducing hepatic steatosis. These data demonstrate the physiological importance of transcription-dependent cis-autoregulatory circuits in metabolic homeostasis and their potential for dysregulation in disease.